FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309658894> ?p ?o ?g. }

• W4309658894 endingPage "e2243449" @default.
• W4309658894 startingPage "e2243449" @default.
• W4309658894 abstract "Importance Delivering low-value care can lead to unnecessary follow-up services and associated costs, and such care cascades have not been well examined in common clinical scenarios. Objective To evaluate the utilization and costs of care cascades of prostate-specific antigen (PSA) tests for prostate cancer screening, as the routine use of which among asymptomatic men aged 70 years and older is discouraged by multiple guidelines. Design, Setting, and Participants This cross-sectional study included men aged 70 years and older without preexisting prostate conditions enrolled in a Medicare Advantage plan during January 2016 to December 2018 with at least 1 outpatient visit. Medical billing claims data from the deidentified OptumLabs Data Warehouse were used. Data analysis was conducted from September 2020 to August 2021. Exposures At least 1 claim for low-value PSA tests for prostate cancer screening during the observation period. Main Outcomes and Measures Utilization of and spending on low-value PSA cancer screening and associated care cascades and the difference in overall health care utilization and spending among individuals receiving low-value PSA cancer screening vs those who did not, adjusting for observed characteristics using inverse probability of treatment weighting. Results Of 995 442 men (mean [SD] age, 78.0 [5.6] years) aged 70 years or older in a Medicare Advantage plan included in this study, 384 058 (38.6%) received a low-value PSA cancer screening. Utilization increased for each subsequent cohort from 2016 to 2018 (49 802 of 168 951 [29.4%] to 134 404 of 349 228 [38.5%] to 199 852 of 477 203 [41.9%]). Among those receiving initial low-value PSA cancer screening, 241 188 of 384 058 (62.8%) received at least 1 follow-up service. Repeated PSA testing was the most common, and 27 268 (7.1%) incurred high-cost follow-up services, such as imaging, radiation therapy, and prostatectomy. Utilization and spending associated with care cascades also increased from 2016 to 2018. For every $1 spent on a low-value PSA cancer screening, an additional $6 was spent on care cascades. Despite avoidable care cascades, individuals who received low-value PSA cancer screening were not associated with increased overall health care utilization and spending during the 1-year follow-up period compared with an unscreened population. Conclusions and Relevance In this cross-sectional study, low-value PSA tests for prostate cancer screening remained prevalent among Medicare Advantage plan enrollees and were associated with unnecessary expenditures due to avoidable care cascades. Innovative efforts from clinicians and policy makers, such as payment reforms, to reduce initial low-value care and avoidable care cascades are warranted to decrease harm, enhance equity, and improve health care efficiency." @default.
• W4309658894 created "2022-11-29" @default.
• W4309658894 creator A5007693528 @default.
• W4309658894 creator A5009860405 @default.
• W4309658894 creator A5016981103 @default.
• W4309658894 creator A5034656894 @default.
• W4309658894 creator A5052851014 @default.
• W4309658894 creator A5061952939 @default.
• W4309658894 creator A5087546386 @default.
• W4309658894 date "2022-11-22" @default.
• W4309658894 modified "2023-10-01" @default.
• W4309658894 title "Low-Value Prostate-Specific Antigen Test for Prostate Cancer Screening and Subsequent Health Care Utilization and Spending" @default.
• W4309658894 cites W1678840505 @default.
• W4309658894 cites W1989217398 @default.
• W4309658894 cites W1995689399 @default.
• W4309658894 cites W1997941107 @default.
• W4309658894 cites W2002355482 @default.
• W4309658894 cites W2060921163 @default.
• W4309658894 cites W2069145210 @default.
• W4309658894 cites W2073117151 @default.
• W4309658894 cites W2100757676 @default.
• W4309658894 cites W2102080582 @default.
• W4309658894 cites W2134793522 @default.
• W4309658894 cites W2139566281 @default.
• W4309658894 cites W2161362572 @default.
• W4309658894 cites W2169873069 @default.
• W4309658894 cites W2551981389 @default.
• W4309658894 cites W2570796533 @default.
• W4309658894 cites W2587771723 @default.
• W4309658894 cites W2616701598 @default.
• W4309658894 cites W2621594223 @default.
• W4309658894 cites W2885728201 @default.
• W4309658894 cites W2892147080 @default.
• W4309658894 cites W2948332559 @default.
• W4309658894 cites W2953790216 @default.
• W4309658894 cites W2966258052 @default.
• W4309658894 cites W2980539853 @default.
• W4309658894 cites W3034041588 @default.
• W4309658894 cites W3042360459 @default.
• W4309658894 cites W3112856517 @default.
• W4309658894 cites W3121638972 @default.
• W4309658894 cites W3131061841 @default.
• W4309658894 cites W3132003450 @default.
• W4309658894 cites W3136535577 @default.
• W4309658894 cites W3153194268 @default.
• W4309658894 cites W3205276392 @default.
• W4309658894 cites W4200438979 @default.
• W4309658894 cites W4247202410 @default.
• W4309658894 cites W4252039761 @default.
• W4309658894 cites W4253453067 @default.
• W4309658894 cites W4255100288 @default.
• W4309658894 cites W4293677288 @default.
• W4309658894 cites W4294839476 @default.
• W4309658894 doi "https://doi.org/10.1001/jamanetworkopen.2022.43449" @default.
• W4309658894 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36413364" @default.
• W4309658894 hasPublicationYear "2022" @default.
• W4309658894 type Work @default.
• W4309658894 citedByCount "2" @default.
• W4309658894 countsByYear W43096588942023 @default.
• W4309658894 crossrefType "journal-article" @default.
• W4309658894 hasAuthorship W4309658894A5007693528 @default.
• W4309658894 hasAuthorship W4309658894A5009860405 @default.
• W4309658894 hasAuthorship W4309658894A5016981103 @default.
• W4309658894 hasAuthorship W4309658894A5034656894 @default.
• W4309658894 hasAuthorship W4309658894A5052851014 @default.
• W4309658894 hasAuthorship W4309658894A5061952939 @default.
• W4309658894 hasAuthorship W4309658894A5087546386 @default.
• W4309658894 hasBestOaLocation W43096588941 @default.
• W4309658894 hasConcept C121608353 @default.
• W4309658894 hasConcept C126322002 @default.
• W4309658894 hasConcept C160735492 @default.
• W4309658894 hasConcept C162324750 @default.
• W4309658894 hasConcept C2775941076 @default.
• W4309658894 hasConcept C2780192828 @default.
• W4309658894 hasConcept C2781406297 @default.
• W4309658894 hasConcept C50522688 @default.
• W4309658894 hasConcept C512399662 @default.
• W4309658894 hasConcept C71924100 @default.
• W4309658894 hasConcept C72563966 @default.
• W4309658894 hasConceptScore W4309658894C121608353 @default.
• W4309658894 hasConceptScore W4309658894C126322002 @default.
• W4309658894 hasConceptScore W4309658894C160735492 @default.
• W4309658894 hasConceptScore W4309658894C162324750 @default.
• W4309658894 hasConceptScore W4309658894C2775941076 @default.
• W4309658894 hasConceptScore W4309658894C2780192828 @default.
• W4309658894 hasConceptScore W4309658894C2781406297 @default.
• W4309658894 hasConceptScore W4309658894C50522688 @default.
• W4309658894 hasConceptScore W4309658894C512399662 @default.
• W4309658894 hasConceptScore W4309658894C71924100 @default.
• W4309658894 hasConceptScore W4309658894C72563966 @default.
• W4309658894 hasIssue "11" @default.
• W4309658894 hasLocation W43096588941 @default.
• W4309658894 hasLocation W43096588942 @default.
• W4309658894 hasLocation W43096588943 @default.
• W4309658894 hasOpenAccess W4309658894 @default.
• W4309658894 hasPrimaryLocation W43096588941 @default.
• W4309658894 hasRelatedWork W1966688579 @default.
• W4309658894 hasRelatedWork W2002790620 @default.

• next